Nexcelom Bioscience, LLC

ntration and viability." Since then, Nexcelom has expanded the product range to accommodate researchers analyzing small cells, primary cells, and researchers looking to perform cell-based assays. With multiple patents pending, Nexcelom is a clear leader and innovator in the field of image-based cytometry for cell analysis. Proven Performance

Thousands of customers, including the top ten pharmaceutical companies, have come to rely on Cellometer instruments for automated cell concentration & viability analysis. "The Cellometer has provided a much faster and more accurate method of counting the 100s of samples we need to set up for flow cytometry analysis." - Dr. Janice Pluth, Lawrence Berkeley Laboratory

From the large breweries performing yeast fermentation monitoring to specialized pharmaceutical labs analyzing fragile hepatocytes for toxicology studies, researchers in a wide range of industries have integrated Cellometer instruments into their laboratory testing. Dedicated Applications Support

Nexcelom is focused on providing novel tools to meet the specific needs of today's researchers. Our applications specialists are in the field with customers every day, analyzing new cell types, validating new cell-based assays, and exploring new therapeutic areas. "Through joint application development, we learn from our customers, the experts in their fields, and assist with integration into their current work flows."- Dr. Bo Lin, Director of Applications Development

Our experienced technical support and applications specialists are committed to ensuring products work successfully in the customer's hands and are always eager to provide support via the phone, internet, and on-site visits. Continued Growth and Innovation

The new Vision CBA Analysis System fulfills a growing customer need for a simpler, more user-friendly method for analysis of apoptosis, cell cycle, and other cell-based assays, as an alternative to flow cytometry. "This new system exemplifies how we extend our Cellometer technology platform to meet the evolving customer needs. In this case, we enable cell based assays with a very limited amount of cells, as we continue to make an impact with cytometry on the biology lab bench." - Dr. Peter Li, President and CEO

Nexcelom will continue to develop novel products, including enhanced instrumentation and specialized reagents, to meet emerging customer needs.